AccurEdit Therapeutics, a Suzhou‑based CRISPR gene‑editing startup, closed a $75 million financing to advance its pipeline of in‑vivo and ex‑vivo gene editing candidates. The Series A positions the company to accelerate IND‑enabling studies and preclinical programs and marks one of the larger rounds for Chinese gene‑editing biotechs this cycle. AccurEdit said funds will support platform development, delivery optimization, and candidate advancement toward clinical proof‑of‑concept, reflecting continued investor appetite for genome‑editing platforms despite regulatory and technical headwinds internationally.